Introduction
Thrombin, classically known for its central role in hemostasis, is also a potent activator regulating a variety of cellular-mediated events (Jackson and Nemerson, 1980;  Bar-Shavit and Wilner, 1986a ). The enzyme is generated from its zymogen prothrombin through the concerted action of several factors in the blood coagulation pathway and acts to convert fibrinogen to fibrin, the major constituent of a hemostatic plug (Jackson and Nemerson, 1980) . It has been recognized for several years that a-thrombin, the enzymatically active form of thrombin, is capable of initiating proliferation in quiescent fibroblasts (Chen and Buchanan, 1975; Carney and Cunningham, 1978) and macrophage-like cells 1 986a) .
We have recently demonstrated that thrombin can be immobilized onto the subendothelial extracellular matrix (ECM) in a manner that leaves the molecule functionally active and protected from inactivation by antithrombin Ill (AT 111) (BarShavit et al., 1989) . Therefore, under certain conditions, thrombin may be present within the vessel wall exhibiting prolonged and localized activities.
Defining factors that regulate proliferation of cells in the vessel wall provides a continuous challenge. The vascular system is composed of the intimal endothelial cells, lining the lumen and the underlying medial smooth muscle cells (SMCs), both coexisting in a quiescent growth state (Castellot et al., 1982; Ross, 1986) . Unregulated proliferation of the medial SMCs may thus have significant implications in the progression of arterial-wall diseases such as atherosclerosis . Accumulating evidence has indicated that SMC proliferation commences before platelet adherence at sites of lesion and may proceed under conditions where the endothelial lumen remains intact (Ross, 1986) . Therefore, initiation of atherogenesis in vivo does not necessarily require products released from platelets external to the artery and may, in fact, occur within the intact vessel wall via intrinsic mediators. Other factors, released mainly from mononuclear phagocytes, have been described as playing a key role in the progression of vascular diseases. Among these are platelet-derived growth factor (PDGF)-like molecules (DiCorleto and Bowen-Pope, 1983; Shimokado et al., 1985; Martinet et al., 1986) , fibroblast growth factor (FGF) (Baird et al., 1985; Klagsbrun and Edelman, 1989) , and the multipotent mediator interleukin 1 (IL-1) (Libby et al., 1988) . Because under certain circumstances thrombin may be present within the vessel wall, firmly bound to the subendothelial basement membrane (Bar-Shavit et al., 1989) , we investigated whether it can also serve as a growthpromoting factor of vascular SMCs. Our data indicate that nonenzymatic thrombin is mitogenic for vascular SMCs, either when present in solution or when sequestered onto the subendothelial ECM. In its bound form thrombin may yield a more localized and persistent stimulation of SMC proliferation compared with its activity in the fluid phase.
Results
Stimulation of arterial SMC proliferation by a-thrombin and DIP-a-thrombin Addition of either native a-thrombin or esterolytically inactive form of diisopropyl fluorophosphate-conjugated thrombin (DlP-conjugated athrombin) to quiescent SMCs resulted in stimulation of DNA synthesis (Figure 1 ). This finding is in contrast to the mitogenic effect of thrombin on human (or bovine, data not shown) skin fibroblasts, where only the enzymatically active thrombin was capable of inducing cell proliferation (Figure 1) . The bin on SMCs was observed over a wide range of concentrations (0.1 nM-1 ,M), with halfmaximal response at 1 nM. Both forms of thrombin elicited the same degree of response in SMCs, as indicated by a five-to sixfold stimulation of 3H-thymidine incorporation, measured 48 h after exposure to the mitogen. Because thymidine incorporation alone may not be a sufficient index for cellular proliferation, we also measured the effect of thrombin on cell number. As indicated in Figure 2 , both a-thrombin and DIP-a-thrombin induced a two-to fourfold increase in cell number over a period of 1-5 d. Cells in S phase were visualized by autoradiography of 3H-thymidine-labeled nuclei. Cells arrested at Go/G1 phase were incubated either with a-thrombin, DIP-a-thrombin, or basic FGF (bFGF) in the presence of 5 ,uCi/ml 3H-thymidine for 24 h. At this time, plates were washed, fixed, and processed for autoradiography. The data revealed that 65%-80% of the nuclei were labeled after incubation with either a-thrombin, DIP-a-thrombin, or bFGF, whereas arrested cells exhibited <50/o labeled nuclei (Figure 3 ).
These results indicate that, under our experimental conditions, the majority of the cells responded to a-thrombin or DIP-a-thrombin and progressed to S phase. Fig. 4 , the chemotactic peptide CB67-129 (derived from thrombin) and the macrophage mitogenic "loop B" peptide (Bar-Shavit et al., 1986a; Bar-Shavit and Wilner, 1986a,b) , failed to elicit incorporation of 3H-thymidine in quiescent SMCs.
The specificity of thrombin-induced SMC proliferation was demonstrated by selective blocking of 3H-thymidine incorporation in the presence of hirudin. This leech-derived thrombin inhibitor inhibited proliferation of those SMCs induced by DIP-a-thrombin, but not those induced by serum ( Figure 5 ). The fact that hirudinblocked thrombin induced mitogenicity in SMCs indicates that the mitogenic domain for SMCs may reside in the vicinity of thrombin' cell interaction exosite, described for macrophages by Bar-Shavit et al. (1 986a).
DIP-a-thrombin induces a rapid and transient expression of c-fos protooncogene in arterial SMCs Addition of growth factors (i.e., serum, PDGF, IL-1) to fibroblasts or SMCs rapidly induces mRNA that encodes the c-fos protooncogene (Libby et al., 1988) . The product of this gene is a nuclear-associated protein that may be involved in signaling the early events in commitment of cellular division (Greenberg and Ziff, 1984; Kruijer et al., 1984; Muller et al., 1984; Kindy and Sonenshein, 1986) . Because thrombin was found to stimulate SMC DNA synthesis in a nonenzymatic fashion, we tested the effect of DIP-a-thrombin on c-fos protooncogene transcript levels. Northern blot analysis revealed that RNA isolated from DlP-a-thrombin-treated SMC cultures contained elevated levels of c-fos transcript compared with non-stimulated cells ( Figure 6 ). This increase reached maximal levels after 30 min incubation with DIP-a-thrombin, decreased back to control levels by 90 min, and remained unchanged thereafter, up to 4 h. Similar effects on the expression of c-fos mRNA were observed with PDGF and other growth factors, demonstrating that DIP-a-thrombin induces early events typical to growth-committed cells.
Binding of 1251-a-thrombin to SMCs Thrombin induction of SMC proliferation suggests the existence of specific receptors on the surface of these cells. Therefore, experiments were performed to characterize such receptor(s) in terms of binding affinity, binding capacity, and time required for obtaining maximal 1251-a-thrombin binding to SMCs. As demonstrated in Figure 7 , an apparent saturation of 1251-a-thrombin binding was achieved at a concentration of 15 (Glenn et al., 1980; Perdue et al., 1981) or macrophages (7.5 X 1 09'M) (Bar-Shavit et al., 1986b; Kindy and Sonenshein, 1986; Ross, 1986) . Competition studies with either native athrombin or DIP-a-thrombin revealed the same inhibition curve of 1251-a-thrombin binding to component representing the product of the cross-linking reaction ( Figure 9 , lanes a, c, and e). This result suggests that the apparent molecular mass of thrombin receptor on SMCs is 55 kDa. Cross-linking of 1251-a-thrombin to its specific cell-surface receptors was inhibited in the presence of excess unlabeled thrombin ( Figure 9 , lanes b, d, and f).
ECM-bound thrombin is mitogenic for vascular SMCs
It has been proposed that one of the roles of extracellular matrices in vivo is to sequester and stabilize biologically active molecules to provide a more localized and persistent stimulation of surrounding tissues (Smith et al., 1982; Knudsen et al., 1986 (Rogelj et al., 1989) was employed. As shown in Figure 10 , PF-HR-9 ECM-bound thrombin was capable of promoting a three-to fourfold stimulation of vascular SMC proliferation, compared with cells maintained on PF-HR-9 ECM alone (which had no effect on SMC growth). The observed stimulation of DNA synthesis in SMCs was specific for thrombin, because complexes formed with the leech-derived polypeptide thrombin inhibitor, hirudin, were devoid of mitogenic activity. Hirudin itself had no effect on either arrested or serum-stimulated SMCs. The fact that hirudin blocked thrombin-induced 3H-thymidine incorporation may indicate that the SMC mitogenic domain resides perhaps in the vicinity of the chemotactic site. In fact, our data demonstrate that thrombin-derived chemotactic peptide competed with 1251-a-thrombin binding to SMCs (Figure 8 ), although it was incapable of promoting cell division (Figure 4) (Ross, 1986; Ross et aL, 1986 ). The present study demonstrates that the serine protease thrombin contains a potent mitogenic activity for vascular SMCs, distinct from its catalytic site. Although its classical role as a procoagulant agent is well known, thrombin is now emerging as a growthpromoting factor. The first observation was made in fibroblasts (Chen and Buchanan, 1975) , where it was demonstrated that only the intact, fully active enzyme can stimulate cells to proliferate. Unlike fibroblasts, thrombin-treated macrophage-like cells enter S phase totally independent of thrombin proteolytic site. The macrophage growth-promoting domain was found to reside in a specific cell-recognition exosite region of thrombin B-chain, separate and distinct from its proteolytic center (BarShavit et al., 1986a,b) . Likewise, thrombin function as a selective chemotaxin toward cells of the mononuclear-phagocytic lineage is mediated through a nonenzymatic site, located at residues 338-400 of thrombin B-chain (BarShavit et al., 1983b; Bar-Shavit and Wilner, 1986a) and containing the "Loop B" mitogenic domain (Bar-Shavit et al., 1986a (Kramer and Vogel, 1983) , AT III (Rosenberg, 1977) , or heparin cofactor 11 (Tollefsen et al., 1982) . Thrombin mitogenic effect is initiated through interaction with specific cell-surface receptors on SMCs. The apparent dissociation constant of this interaction (6 nM) correlates with thrombin mitogenic activity, reaching a half-maximal effect at -1 nM. The number of binding sites was similar to that previously found in fibroblasts and macrophage-like cells (-500 000/ cell) (Perdue et al., 1981; Bar-Shavit et al., 1 983a; Carney and Cunningham, 1978) . Thrombin-specific receptors on SMCs recognize both native and nonenzymatic DIP-a-thrombin to a similar extent and, with lower affinity, the thrombin-derived chemotactic fragment CB67-129. This cell-surface receptor appeared to be a 55-kDa protein, as indicated by its specific cross-linkage with 1251-a-thrombin.
Thrombin is generated traditionally in response to vascular injury, leading to platelet adhesion and aggregation on the surface of the exposed subendothelium to establish a fibrin clot. Under normal conditions, however, when the integrity of the subendothelium is retained, thrombin has been shown to induce gap formation between adjacent endothelial cells in a rapid, non-cytotoxic, reversible manner (Laposata et al., 1983; Garcia et al., 1986) . Thus, thrombin, when generated under certain circumstances on the luminal surface of the endothelium (Stern et al., 1985) , may pass through the endothelial cell layer and reach subendothelial structures. In addition, during the process of fibrin-clot formation, thrombin may become trapped within the fluid phase of the fibrin gel (Kaminski et al., 1983; Wilner et al., 1981) . This thrombin can be recovered intact and active on fibrinolysis and hence may become accessible to the vascular subendothelium. Our studies on the properties and biological activity of ECMbound thrombin demonstrate that immobilized thrombin is a potent mitogen for vascular SMCs, while being protected from inactivation by its physiological inhibitor AT III (Bar-Shavit et al., 1989) . Thrombin sequestered by subendothelial ECM may thus be involved in the progression of the atherosclerotic process.
Serine proteases are closely related proteins descending perhaps by splicing of a common gene ancestor (Neurath, 1984) . The cDNA sequences of the human and bovine prothrombin gene have been determined (Craik et al., 1982;  MacGillivray and Davie, 1984) . Beyond the 10 y-carboxyglutamic acid residues, which are vitamin K-dependent and posttranscriptionally synthesized (Magnusson et al., 1975) , two "kringle" structures are found, implying tandem gene duplication. This double kringle structure is also found in tissue plasminogen activator (Ny et al., 1984) , which on activation expresses a substrate specificity similar to that of a-thrombin (Lijnen et al., 1984) but differs from prothrombin in many other aspects. The fact that thrombin exhibits functional domain(s) distinct from its catalytic site provides evidence that despite a common ancestor gene, thrombin has acquired genes inserted at exon-intron junctions (Craik et al., 1982) to yield the divergence of amino acid sequences with unique hormone-like functions. It is not unlikely that such growthpromoting sequences might be synthesized also by various cells recruited to wounded or inflamed regions within the vessel wall.
The present study demonstrates nonenzymatic activity of a serine protease residing in a distinct domain separate from the proteolytic site. Under certain conditions, thrombin may be immobilized onto the vascular subendothelium, where it may express its functional activities (chemotaxis, mitogenesis) and yield a considerably prolonged and localized mitogenic stimulation of SMCs, thus directly contributing to the progression of atherosclerosis.
Materials and methods Cells
SMCs were isolated from the bovine aortic media as previously described (Castellot et al., 1982) . Briefly, the abdominal segment of the aorta was removed and the fascia cleaned away under a dissecting microscope. The aorta was cut longitudinally, and small pieces of the media were carefully stripped from the vessel wall. Two or three such strips with average dimensions of 2 x 2 mm were placed in 60-mm-diam tissue culture dishes (Falcon Labware Division, Becton Dickinson, Oxnard, CA) that contained Dulbecco's modified Eagle's medium (DMEM; 1 g glucose/I) supplemented with 10% FCS, 100 U/mI penicillin, and 100 Ag/ml streptomycin (GIBCO, Grand Island, NY). Within 7-14 d, large patches of multilayered cells had migrated from the explants. Approximately 1 wk later, SMCs from a 60-mmdiam tissue culture dish were subcultured into a 100-mm tissue culture plate (-4-6 x 105 cells/plate). The cultures (passage 3-8) exhibited typical morphological characteristics of vascular SMCs, and the cells were specifically stained with monoclonal antibodies that selectively recognize muscle form of actin . This antibody does not recognize endothelial cells or fibroblasts (Tsukada et al., 1987) . Foreskin fibroblasts (passage 3-9) were maintained in DMEM (1 g glucose/I) supplemented with 10% FCS and antibiotics as described above. PF-HR-9 cells derived from a differentiated mouse endodermal carcinoma (Chung et al., 1978; Rogelj etal., 1989) were maintained in DMEM (4.5 g glucose/ I) containing 1 0% FCS and antibiotics. Cells were maintained at 370C in 80/% C02-humidified incubators and subcultured weekly at a 1:10 split ratio after dissociation with saline containing 0.05% trypsin, 0.01 M sodium phosphate, pH 7.2, and 0.02%o EDTA (Biological Industries, Bet-Haemek, Israel).
Preparation of dishes coated with ECM
For preparation of PF-HR-9 ECM, cells (105/35-mm dish) were seeded into tissue culture dishes precoated with fibronectin (50 Ag/dish) (kindly provided by Kabi Vitrum AB, Stockholm, Sweden) to enforce a firm adhesion of the ECM to the plastic substratum. Ascorbic acid (50 jig/ml) (Sigma Chemicals, St. Louis, MO) was added on days 2 and 4. Six to seven days after seeding the cells, the ECM was exposed by dissolving (3 min at 220C) the cell layer with a solution containing 0.5% Triton X-100 and 20 mM NH40H in phosphate-buffered saline (PBS), pH 7.4, followed by four washes in PBS (Gospodarowicz et al., 1984) . Major constituents of the HR-9-ECM were laminin, entactin, collagen type IV, and heparan sulfate proteoglycans (Kramer and Vogel, 1984; Gospodarowicz et al., 1984) . PF-HR-9 cells were shown to produce ECM devoid of bFGF (Rogelj et al., 1989) . This ECM did not promote the proliferation of vascular endothelial cells and SMCs.
Human thrombin preparations
Highly purified human a-thrombin was prepared from fraction III paste, evaluated for purity, and characterized as described previously (Fenton et al., 1977a,b; Perdue et al., 1981) . Specific clotting activity of the a-thrombin preparation was 3975 U/mg. The preparation used in the experiments consisted of 98Yo a-, 1.8% ,B-, and 0.70/o y-thrombins and was titrated to >85% active enzyme with p-nitrophenyl-pguanidinobenzoate (NPGB). -y-Thrombin. a-Thrombin was converted essentially to -ythrombin by controlled passage of a-thrombin through trypsin immobilized on agarose at pH 6.2. The preparation was titrated to 79% esterase activity with NPGB, and was composed of 0.4% a-, 15.2% ,8-, and 84.4%o y-thrombin. It possessed only 1.7 U/mg clotting activity.
N02-a-thrombin. a-Thrombin was nitrated as described before (Perdue et al., 1981) by the use of tetranitromethane at pH 7.8. Specific activity was reduced from 3975 to 14 clotting U/mg and the NPGB-titratable active sites were reduced from 84.4%o to 66%. DIP-a-thrombin. a-Thrombin with a specific activity of 2800 U.S. clotting units/mg was treated repeatedly with 0.2M DIP at pH 8.0 for 30 min until clotting activity was diminished to -0.5 U/mg and active esterolytic titrable sites were reduced to an undetectable level, as described previously (Perdue et al., 1981) . MeSO2-a-thrombin. a-Thrombin was treated with excess MeSO2-F for 30 min at 24°C and dialyzed overnight against 0.75 M NaCI to remove unbound inhibitor. Clotting activity of MeSO2-a-thrombin was reduced from 3975 U/mg to 1.2 U/mg; NPGB esterase activity was negligible. TLCK-a-thrombin. a-Thrombin was alkylated by repeated treatment at pH 7.4 with an -1 00-fold molar excess of TLCK over a period of 2 h until clotting activity was reduced from 3975 to 0.85 U/mg and esterase activity, estimated by titration with NPGB, was reduced from -85% to 7%.
Preparation of the catalytically inactivated fibrinopeptide exosite affinity label D-Phe-Pro-Arg-CH2-a-thrombin (PPACK-a-thrombin) was performed as described before (Fenton et al., 1977a,b) .
Modified thrombin preparations were dialyzed against 0.75 M NaCI and stored frozen at -700C.
lodination of thrombin
Radiolabeling of thrombin was carried out by the use of the lodogen method as described by Glenn et al. (1980) . Briefly, lodogen (Pierce, Rockford, IL) was dissolved at 1 mg/ml in CH2CI2; 100 ul of this solution was placed in a glass tube (10 x 75 mm) and the lodogen was coated on the surface by drying under a stream of N2. Approximately 100 jg of athrombin and 1.0 mCi Na1251 (1 O0mCi/ml, carrier free; International Amersham, UK) were added to 0.1 M NaCI containing 50 mM sodium phosphate, pH 7.0, and 160MuM benzamidine. The mixture was added to the lodogen-coated tube and incubated for 10 min at 40C. lodination was terminated by removing the reaction mixture from the lodogencoated tube. Free iodine and benzamidine were removed by gel filteration (Bio-Gel P-2; Bio-Rad Laboratories, Richmond, CA) and dialysis against 0.75 M NaCI buffered with 50 mM sodium phosphate, pH 7.0, at 40C. The 1251-labeled preparations had a specific activity of 5-10 x 106 cpm/Mg and comigrated as a single band with unlabeled thrombin on SDS-PAGE. 1251-a-thrombin retained nearly 100% of its catalytic activity (measured by Chromozyme-TH assay, Sigma Chemicals, St. Louis, MO) and mitogenic activities.
3H-thymidine incorporation
SMCs were plated at an initial density of 4 x 104 cells/well in 24-well plates (16-mm diameter) (Nunc, Roskilde, Denmark) in DMEM supplemented with 10% FCS. Twenty-four hours after seeding, medium was replaced with medium containing 0.2% heat-inactivated FCS, and, 48 h later, the cells were exposed to growth stimulants for an additional 24-48 h. DNA synthesis was assayed by measuring the radioactivity incorporated into trichloro acetic acid-insoluble material after labeling the cells with 3H-thymidine (1 MACi/ well) (500 mCi/mmol; New England Nuclear, Boston, MA) for a period of 24 h, as described by Bar-Shavit et al. (1 986a).
Cell proliferation assay
SMCs were seeded and exposed to growth stimulants as described above. One to six days after seeding, the cells were fixed with 2.5% formaldehyde in PBS. The plates were immersed in a bath of 0.01 M borate buffer (pH 8.5), stained (10 min at 240C) with 0.1 ml methylen blue/well (1 % in 0.1 M borate buffer, pH 8.5), and washed four times in borate buffer. This procedure removed practically all non-cell-bound dye. Specific cell-incorporated methylen-blue was dissolved with 0.2 ml of 0.1 N HCI (40 min at 370C) and determined by reading the absorbance at 600 nm. Uptake of methylen blue was linearly correlated to the number of viable cells (Goldman and Bar-Shavit, 1979 ).
Binding of 1251-a-thrombin to SMCs
Cells were grown to confluency in 16-mm culture wells (5 X 1 05 cells/well). Confluent cultures were transferred to 4°C, washed once with PBS followed by 1 h incubation in PBS containing 1 Yo bovine serum albumin (BSA). 1251-a-thrombin was then added at the indicated concentration, and, afterthrombin was added to confluent SMC cultures in the presence and absence of 1 000-fold excess unlabeled thrombin. After 4 h incubation at 4°C, the cells were washed extensively with PBS, then incubated (30 min, 370C, gentle mixing) with the bifunctional cross-linker EDC (increasing concentrations up to 1 mM) in PBS containing 10/0 BSA at pH 6.5. At the end of this period, samples were washed and dissolved in SDS-polyacrylamide sample buffer for analysis on SDS-PAGE.
Autoradiography of labeled nuclei
Autoradiography was carried out by incubating quiescent SMCs with DMEM containing 0.2%o calf serum and 5 ,Ci/ ml 3H-thymidine in the presence and absence of exogenous growth factors for 24 h. At this time, plates were washed extensively with PBS, fixed with methanol (10 min, 400), and dried. The dishes were then coated with Ilford K5 photographic emulsion, incubated for 5 d, and developed with Kodak D-19 developer.
RNA isolation
RNA was isolated according to the method of Chomczynski and Sacchi (1987) . Cell monolayers were solubilized in a minimal volume (0.5-1 ml) of solution containing 4 M guanidinium thiocyanate (Fluka), 25 mM sodium citrate, pH 7.0, 0.5%/o sarcosyl and 0.092 M 2-mercaptoethanol. The solubilized material was incubated overnight at 370C. Extraction with phenol and chloroform was then performed, and the RNA-containing aqueous phase was precipitated in ethanol.
Capillary transfer of RNA to GeneScreen (Northern blot)
Fractionation of RNA on an agarose gel was carried out by modification of a described method (Lehrach et al., 1977) . Briefly, RNA samples were separated on 1% agarose gel containing 1.1 M formaldehyde. After electrophoresis, the gel was transferred to GeneScreen membrane in 20x SSPE (174 g NaCI, 27.6 g NaH2PO4 H20, and 7.4 g EDTA per 1 1, pH 7.4) and baked in a vaccum oven at 800C for 2 h. Detection of target RNA species was carried out after hybridization with randomly labeled 32P-c-fos DNA probe (American Type Culture Collection, isolated from human lymphoblast cell line CCRF-CM) with the use of 32P-dCTP (Pharmacia; Upssala, Sweden) at -0.5-1 x 107 cpm/filter. Hybridization was carried out with 330/o formamide at 42°C for crossspecies hybridization. Specifically hybridized RNA was detected on exposure to X-ray film.
